ViiV, Shionogi to Copromote Anti-HIV Drug Tivicay at 100 Major Facilities

From Left: ViiV President Hirohisa Iriyama, UK CEO Dominique Limet, and Shionogi President Isao Teshirogi ViiV Healthcare K.K. and Shionogi are now gearing up to copromote the HIV treatment Tivicay (dolutegravir), a HIV integrase inhibitor approved on March 24, in...read more